CRDFCardiff OncologyFinished
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
Colorectal Cancer · Metastatic Colorectal Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Dec 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 23 (final count)
- Started
- Mar 17, 2023
- Main results expected
- Dec 9, 2024
- Fully finished
- Dec 9, 2024
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate
Measured over: Up to approximately 1 year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-12-09, no fading
Raw record changes
- none yet
Trial ID NCT05593328 · record last updated 2025-01-10 · checked 2026-11-09 15:47 UTC